Viewing Study NCT03959761


Ignite Creation Date: 2025-12-24 @ 12:22 PM
Ignite Modification Date: 2026-01-31 @ 7:40 AM
Study NCT ID: NCT03959761
Status: COMPLETED
Last Update Posted: 2025-12-19
First Post: 2019-05-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma
Sponsor: Hospices Civils de Lyon
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ovarian Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Immunotherapy View
None Debulking surgery View
None Hyperthermic Intraperitoneal Chemotherapy (HIPEC) View